P&G Patents Topical Oral Care Composition
Published November 6, 2012
US Patent No. 8,277,782 B2; Procter & Gamble has been awarded patent coverage for a topical oral care composition for controlling oral cavity bacterial infection and reducing risk of developing an oral bacteria-induced systemic disease in humans and other animal subjects. The composition consists of a safe and effective amount of a combination of antioxidant and H2-antagonist host-response modulating agents, wherein the antioxidant is selected from one or a mixture of gallic acid, N-acetyl cysteine, or anethole dithiolthione and the H2-antagonist is selected from one or a mixture of cimetidine, etintidine, ranitidine, tiotidine, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, zaltidine, nizatidine, mifentidine, ramixotidine, loxtidine, bisfentidine, sufotidine, ebrotidine or impromidine; a safe and effective amount of an additional oral therapeutic active selected from one or a mixture of antimicrobial/antiplaque agents selected from benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride, tetradecylpyridinium chloride and N-tetradecyl-4-ethylpyridinium chloride; and a pharmaceutically-acceptable oral carrier.
blog comments powered by Disqus